AddedRisk Factors
We have in the past and may in the future be the focus of shareholder activism, which has become increasingly prevalent. Shareholder activism, particularly with respect to matters that our Board, in exercising its fiduciary duties, disagrees with, or has determined not to pursue, may adversely affect our business because responding to activist shareholders can be costly and time-consuming, disruptive to operations and divert the attention of our Board and management. Our ability to execute our strategic plan could also be impaired as a result. Responding to an activist campaign could cause us to incur substantial fees and expenses and could also lead to litigation, which could be a further distraction to our Board and management and require us to incur significant additional costs.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedRisk Factors
Perceived uncertainties as to our future direction, strategy or leadership created as a consequence of activist shareholders may result in the loss of potential business opportunities, harm our ability to attract new or retain existing investors, lenders, customers, directors, employees, or other partners, and negatively affect or create volatility in our stock price.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RemovedRisk Factors
As we refine our business model, we may also pursue divestitures in line with our new operating model. For example, in October 2024, we divested our Clinical Services business, a component of our Laboratory Solutions reportable segment. We also plan to continue expanding our commercial sales operations and scope and complexity of our business both domestically and internationally, while maintaining our commercial operations and administrative activities. Our ability to manage our business and conduct our
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedRisk Factors
•development of large and sophisticated group purchasing organizations and on-line auction sites that increase competition for, and reduce spending on, laboratory products;
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedRisk Factors
•consolidation of biopharmaceutical companies resulting in a rationalization of research expenditures;
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedRisk Factors
•increased regulatory scrutiny over drug production requiring safer raw materials;
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedRisk Factors
•customers’ purchasing the products that we supply directly from our suppliers; and
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedRisk Factors
Given the nature of our business, we collect and store confidential information that customers provide in order to, among other things, purchase products and services and register on our website.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedRisk Factors
refrain from purchasing our brands in the future and in turn could impair our brand equity and adversely affect our sales.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedRisk Factors
components could be impacted by the availability and price of those raw materials and maintaining relationships with key suppliers.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedRisk Factors
The U.S. Congress, foreign governments, and their agencies in non-U.S. jurisdictions where we and our affiliates do business, and the Organization for Economic Cooperation and Development (“OECD”),
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedRisk Factors
and material violations of such standards of conduct could occur that could have a material effect on our business, reputation and financial statements.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedRisk Factors
•making it more difficult for us to satisfy our debt or contractual obligations;
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedRisk Factors
•exposing us to the risk of increased interest rates as certain of our borrowings, including borrowings under our senior secured credit facilities, are at variable rates of interest;
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RewordedRisk Factors
Like other companies, the systems and networks we maintain and third-party third party systems and networks we use have in the past been, and will likely in the future be, subject to or targets of unauthorized or fraudulent access, including physical or electronic break-ins or unauthorized tampering, as well as attempted cyber and other security threats and other attacks such as “denial of service” attacks, phishing, untargeted but sophisticated and automated attacks, ransomware, and other disruptive software.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our subsidiaries may be required to register for permits and/or licenses with, and may be required to comply with, the laws and regulations of the FDA, the DHHS, the DEA, foreign agencies including the EMA, and other various state health departments and/or comparable state and foreign agencies as well as certain accrediting bodies depending upon the types of operations and locations of distribution and sale of the products manufactured or services provided by those subsidiaries.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
We cannot be certain that identification of presently unidentified environmental, health and safety conditions, new regulations, more vigorous enforcement by regulatory authorities or other unanticipated events will not arise in the future and give rise to additional environmental liabilities, business interruptions, compliance costs or penalties, which could have an adverse effect on our business, financial condition and results of operations.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
(vi) escalation of geopolitical tensions or potential changes in diplomatic and trade relationships, including potential changes under the second Trump administration to trade restrictions, tariffs and exchange controls and political and trade uncertainty in China; China along with potential retaliatory tariffs by other countries;
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
We also rely on our suppliers to adhere to our supplier standards of conduct, and material violations of such standards could occur that could have a material effect on our business, reputation and financial statements.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our exclusive forum provision shall not relieve the company of its duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
While it is uncertain whether the U.S. will enact legislation to adopt the minimum tax directive, certain Certain countries in which we operate have adopted legislation and other countries are in the process of introducing legislation to implement the minimum tax directive.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our ability to maintain an adequate supply of such materials could be impacted by the availability and price of those raw materials and maintaining relationships with key suppliers.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
The failure inability to identify, attract, retain and properly motivate members of our senior management team and other key employees, or to find suitable replacements for them in the event of death, illness or their desire to pursue other professional opportunities, could have a negative effect on our operating results.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Failure Changes to compete successfully could trade policy, including new or increased tariffs and changing import/export regulations, may adversely affect our business, financial condition and results of operations.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
We devote significant resources and time to comply with the internal control over financial reporting requirements of the Sarbanes Oxley Act of 2002 and continue to enhance our controls.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Failure to comply with these ISO standards can lead to observations of non-compliance or even suspension of ISO or Aerospace Standard (AS) certifications or European Community (EC) Declarations of Conformity Certificates by the registrar.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
In the fourth quarter of 2025, we issued €400.0 million and €550.0 million of senior secured term loans, maturing in October 2030 and October 2032, respectively. These loans bear interest at EURIBOR plus 150 basis points and EURIBOR plus 250 basis points, respectively. The proceeds from these issuances, along with cash on hand, were used to repay our outstanding U.S. dollar term loans B-6, Euro term loans B-4, Euro term loans B-5, the remaining 2.625% secured notes, and the receivables facility.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
In connection with the refinancing, we amended our revolving credit facility to obtain an additional $425.0 million in available funding, increasing the total availability under the facility to $1,400.0 million.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
The imposition of tariffs and other trade restrictions by the U.S., as well as reciprocal trade restrictions imposed by other countries, could adversely affect global economies, financial markets and the overall environment in which we do business.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
In the third quarter of 2025, we recorded a goodwill impairment charge of $785.0 million related to our Distribution reporting unit, formerly referred to as our Buy Sell reporting unit. This impairment was primarily driven by sustained decreases in our publicly quoted share price and market capitalization, as well as changes in operating results. While the impairment is a non-cash charge, it reflects underlying business conditions that may continue to affect our future results. We are actively implementing initiatives and evaluating strategic actions to mitigate these pressures.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
For the year ended December 31, 2025, net sales declined primarily due to the divestiture of our Clinical Services business within our Advanced Lab Services business and reduced customer demand in the Total Science Solutions business, both of which impacted the Laboratory Solutions segment. Gross margin and gross profit decreased, reflecting lower sales volume, inflationary pressures, the divestiture of our Clinical Services business and higher freight costs. Operating income declined largely due to a non‑cash goodwill impairment charge recorded in the Distribution reporting unit in the current year and the absence of the
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
The following table presents the reconciliation of net (loss) income and net (loss) income margin to Adjusted EBITDA and Adjusted EBITDA margin, respectively:(dollars in millions, % based on net sales) Year ended December 31, 2025 2024 $ % $ % Net (loss) income $ (530.2) (8.1)% $ 711.5 10.5% Interest expense, net 169.8 2.5% 218.8 3.2% Income tax expense 88.9 1.3% 142.4 2.1% Depreciation and amortization 410.2 6.3% 405.5 6.0% Loss on extinguishment of debt 4.6 0.1% 10.9 0.2% Restructuring and severance charges1 29.8 0.5% 82.8 1.2% Transformation expenses2 61.7 1.0% 58.9 0.9% Reserve for certain legal matters, net3 7.3 0.1% 9.2 0.2% Other4 20.9 0.3% (3.9) (0.2)% Impairment charges5 785.0 12.0% — —% Gain on sale of business6 5.1 0.1% (446.6) (6.6)% Pension termination charges7 16.3 0.2% 9.3 0.2% Adjusted EBITDA $ 1,069.4 16.3% $ 1,198.8 17.7%
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
4.Represents other stock-based compensation expense (benefit), $6.7 million of severance and transition costs associated with the replacement of our Chief Executive Officer in 2025, and other costs.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
In October 2025, our Board of Directors authorized the repurchase of up to $500.0 million of our common stock. Repurchases may be funded through available cash, borrowings under existing credit facilities, or other financing arrangements. The program may be modified, suspended, or terminated at any time.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
In November 2025, we repurchased $75.0 million of our common stock. As of December 31, 2025, $425.0 million remained available for repurchase under the program. Refer to Note 15 to the Consolidated Financial Statements included in this Annual Report for additional discussion of our common stock repurchase program.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
As a result of sustained decreases in our publicly quoted share price and market capitalization as well as changes in the operating results of our Distribution reporting unit, we conducted an interim test of our goodwill as of September 30, 2025.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
Based on the results of the impairment test, the carrying amount of our Distribution reporting unit exceeded its fair value, resulting in a non-deductible, non-cash goodwill impairment charge of $785.0 million, which was recorded in the consolidated statement of operations for the three months ended September 30, 2025. We did not identify impairment of any other long-lived assets in this reporting unit. The remaining reporting units tested were not impaired, as their estimated fair values exceeded their respective carrying amounts as of the interim testing date.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
Following the impairment charge, the carrying value of the Distribution reporting unit is equal to its estimated fair value. Recognition of additional impairment charges may be required in future periods if market conditions, projected results, or other valuation assumptions deteriorate further.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RemovedMD&A
Our business continues to be impacted by the transition from the global COVID-19 pandemic
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
Customer demand and required inventory levels continue to normalize in the transition from the COVID-19 pandemic. The transition from the outbreak continued to impact the full year results of our two segments, as described further in the “Results of operations” section.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
In June 2023, we amended the revolving credit facility to increase its funding limit up to $975.0 million and extended the term to June 29, 2028.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
In 2024, we made prepayments of $690.0 million and $526.4 million on U.S. dollar term loan B-6 and Euro term loan B-4, respectively, which reduced our variable-rate debt.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
In 2023, the net sales decline was driven primarily by reduced customer demand, the impact of customer destocking, and COVID-19 related headwinds. Unfavorable product mix and inflationary pressures contributed to contraction in gross margin. Operating income was driven primarily by asset impairment charges recorded in 2023. Lower sales volumes along with unfavorable product mix drove Adjusted EBITDA margin contraction and Adjusted Operating Income margin contraction.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
related to the roll off of COVID-19 revenues for diagnostic testing, in addition to reduced customer demand and destocking of lab products.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
In 2023, operating income decreased primarily from lower gross profit, as previously discussed, as well as higher operating expenses driven by asset impairment charges recorded in 2023, accrual of a long-term retention incentive, inflation and investments made to grow the business, partially offset by lower accruals related to incentive compensation.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
1.Represents direct costs incurred with third parties and the accrual of a long-term retention incentive to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
2.Represents the non-cash reduction of contingent consideration related to the Ritter acquisition and the amortization of the purchase accounting adjustment to record Masterflex inventory at fair value.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
1.Represents direct costs incurred with third parties and the accrual of a long-term retention incentive to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RemovedMD&A
operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.
Read it in 10-K Feb 7, 2025 at sec.govopen_in_new
RewordedMD&A
In 2024, net Net (loss) income increased decreased primarily due to higher lower operating income, as previously discussed, as well as and pension termination charges, partially offset by lower interest expense due to resulting from debt repayments on our variable-rate debt, partially offset by higher made over the last twelve months and lower income tax expense due to higher driven by reduced income before income taxes.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
Financing activities used $437.5 provided $871.8 million more cash in 2024 2025, primarily due to higher lower net debt repayments in during the current year, partially offset by higher payments for the repurchase of common stock in 2025 and a decrease in proceeds received from stock option exercises in 2024. compared to the prior year.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
The remaining decline of $113.6 $145.8 million or 8.7% 12.1% was primarily driven primarily by the divestiture of our Clinical Services business and lower gross profit and higher annual incentive compensation expenses, profit, as previously discussed, partially offset by savings from our cost transformation initiative. initiative and lower annual incentive compensation expense.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
In 2023, gross Gross margin decreased 70 90 basis points resulting primarily from due to inflationary pressures, higher freight costs, unfavorable manufacturing variances, unfavorable product mix and the impact divestiture of inflationary pressures, our Clinical Services business, partially offset by lower distribution costs. inventory reserves.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
The change was Investing activities provided $569.4 million less cash in 2025, primarily attributable due to the absence of proceeds received from the sale of our Clinical Services business. business, which were received in the prior year.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
Capacity $ 247.6 $975.0 $ 1,222.6 $1,400.0 Undrawn letters of credit outstanding (15.3) (3.1) (18.4) Outstanding borrowings (125.0) — (125.0) (19.5) Unused availability $ 107.3 $971.9 1,079.2 $1,380.5 Cash and cash equivalents 261.9 365.4 Total liquidity $ 1,341.1 $1,745.9
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease was primarily driven primarily by the divestiture of our Clinical Services business, lower sales volume and higher annual incentive compensation expenses, inflationary pressures, partially offset by savings from our cost transformation initiative. initiative and lower annual incentive compensation expense.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease was primarily driven primarily by lower sales volume volume, unfavorable manufacturing variances and higher annual incentive compensation expenses, freight costs, partially offset by commercial excellence, savings from our cost transformation initiative. initiative and lower annual incentive compensation expense.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
(in millions) Year ended December 31, Change 2025 2024 2023 Net cash provided by operating activities $ 623.8 $ 840.8 $ 870.0 $ (29.2) (217.0) Capital expenditures (128.8) (148.8) (146.4) (2.4) 20.0 Divestiture-related transaction expenses and taxes paid 1.4 76.3 — 76.3 (74.9) Free cash flow $ 496.4 $ 768.3 $ 723.6 $ 44.7 (271.9)
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
These valuation methods require management to make various assumptions, including, but not limited to, future profitability, cash flows, including revenues, gross margin, SG&A expenses, capital expenditures, and investments in debt free net working capital, current market assumptions for the discount rates, weighting of valuation methods and the selection of comparable publicly traded companies.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
We have experienced inventory fluctuations and build up at customers as a result of global supply chain disruptions and have experienced inflationary pressures across all of our cost categories.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new